Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Raises $12.7M in Private Financing

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protagen today said it has raised €10 million ($12.7 million) in a second financing round.

NRW.Bank in Düsseldorf participated in the round as a new investor and joined the consortium of MIG Fonds, S-Capital, S-Venture Capital, and KfW Bonn to finalize the round.

Proceeds will be used for the expansion of Protagen's diagnostics business and to clinically validate proprietary protein biomarkers, the Dortmund, Germany-based firm said. It will focus efforts on developing serum-based molecular diagnostics for the early detection of multiple sclerosis and the differential prognosis of prostate cancer, it said.

The company's UNIarray technology platform also will be used "in other attractive indications for the development of serum-based molecular diagnostics," Protagen added.

The company previously raised €3.7 million in August 2009.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.